Prescription Required.
Saroglitazar is the active ingredient in the medication.It belongs to a class of drugs called peroxisome proliferator-activated receptor (PPAR) agonists.PPARs are nuclear receptors that play a role in regulating lipid metabolism, inflammation, and insulin sensitivity.
Saroglitazar is primarily indicated for the treatment of mixed dyslipidemia, a condition characterized by elevated levels of triglycerides, low levels of highdensity lipoprotein (HDL) cholesterol, and potentially elevated levels of low-density lipoprotein (LDL) cholesterol.
Bilypsa Tab 10s (Saroglitazar) works by activating PPAR alpha and PPAR delta receptors. This activation leads to a reduction in triglyceride levels, an increase in HDL cholesterol levels, and a decrease in LDL cholesterol levels. Additionally, it has anti-inflammatory effects and may improve insulin sensitivity.
Store saroglitazar at room temperature, away from moisture and direct sunlight. Keep it out of reach of children.
The dosage of saroglitazar varies depending on the individual's condition and response to treatment.
It is typically taken once daily with a meal.
Your doctor will determine the appropriate dosage for you.
Less common but more serious side effects may include liver damage, pancreatitis, and increased risk of bleeding.
Common side effects include headache, nausea, diarrhea, and abdominal pain.
Alcohol consumption may increase the risk of liver damage. It is recommended to limit alcohol intake while taking saroglitazar.
Saroglitazar may cause dizziness or drowsiness. It is important to avoid driving or operating machinery until you know how this medication affects you.
The safety of saroglitazar during pregnancy and breastfeeding is unknown. It is recommended to avoid using this medication during pregnancy or breastfeeding unless the benefits outweigh the potential risks.
The safety and efficacy of saroglitazar in children have not been established.
Saroglitazar may affect kidney function. Patients with kidney problems should be monitored closely.
Saroglitazar can cause liver damage. Patients with liver problems should be monitored closely.
Manufacturer's prescribing information
MedlinePlus
Drugs.com
Mayo Clinic
National Institutes of Health (NIH)
